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Abstract
Background: The contribution of birth defects, including cleft lip and palate, to neonatal and infant mortality and
morbidity is substantial. As other mortality and morbidity causes including infections, hygiene, prematurity, and
nutrition are eradicated in less developed countries, the burden of birth defects will increase proportionally.
Methods/Design: We are using cleft lip and palate as a sentinel birth defect to evaluate its burden on neonatal
and infant health and to assess the effectiveness of systematic pediatric care during the first month and first two
years of life in decreasing this burden. The neonatal intervention, consisting of weekly pediatric evaluation and
referral to appropriate care, is delivered to about 696 infants born with cleft lip and/or palate in 47 hospitals in
South America. Neonatal mortality in this group will be compared to that in a retrospective control group of
about 464 infants born with cleft lip and/or palate in the same hospitals. The subgroup of infants with isolated
clefts of both the lip and palate (about 264) is also randomized into two groups, intervened and non-intervened,
and further followed up over 2 years. Intervened cases are evaluated by pediatricians every three months and
referred for appropriate care. The intervened and non-intervened cases will be compared over study outcomes
to evaluate the intervention effectiveness. Non-intervened cases are matched and compared to healthy controls
to assess the burden of cleft lip and palate. Outcomes include child's neurological and physical development and
family social and economic conditions.
Discussion: Large-scale clinical trials to improve infant health in developing countries are commonly suggested,
making it important to share the methods used in ongoing studies with other investigators implementing similar
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research. We describe here the content of our ongoing pediatric care study in South America. We hope that this
may help researchers targeting this area to plan their studies more effectively and encourage the development of
similar research efforts to target other birth defects or infant outcomes such as prematurity and low birth weight.
Background
Neonatal and infant mortality and morbidity are high in
less developed countries. Each year about 10 million chil-
dren die worldwide, with extensive between and within
country variation [1,2]. Almost half of these deaths (about
4 million) occur among newborns before one month of
age [2-4]. The majority (about 95%) of all neonatal deaths
occur in less developed countries, where 34 neonates die
among every 1000 live births, compared to 5 neonates in
developed countries [3,4]. In the past two decades, greater
reductions have been observed in child mortality than in
neonatal mortality with the lowest reductions observed in
the early neonatal phase [4], leading to a greater number
of deaths within the first month of life.
Among the main causes of neonatal mortality in develop-
ing countries (infections, prematurity complications, and
birth asphyxia), congenital anomalies constitute the
fourth leading cause, and are responsible for about 7–
10% and 3.8% of neonatal and under – 5 mortality,
respectively [1,3,4]. Congenital malformations are
increasingly contributing to overall infant mortality in
developed countries such as the United States [5], where
20% of infant deaths in 2001 were related to congenital
malformations [6]. The burden of birth defects will also
be expected to increase in developing countries as public
health, nutrition, and other primary health interventions
succeed in reducing main mortality and morbidity causes
such as infections and low birth weight. Besides mortality,
birth defects also increase the risk for disability. In 2002,
more than 27 million lost Disability Adjusted Life Years
(DALYs) forming about 1.8% of the overall burden of dis-
ease were related to congenital abnormalities [1].
Oral clefts are common birth defects that affect about 1 in
every 700 births with varying prevalence by population
origin and socioeconomic status [7,8]. Cleft lip and palate
occurs as both isolated and syndromic forms [9]. Isolated
forms are unassociated with any other structural or cogni-
tive birth defects. Syndromic forms of clefts have a wide
range of etiologies with more than 400 reported in Online
Mendelian Inherited Diseases in Man [10] from single
gene causes and with other clefts occurring secondary to
chromosomal anomalies, teratogenic exposures, and as
sporadic disorders without recognized etiologies.
Isolated forms are readily targeted by care provided by
multi-specialty teams yet may still have substantial infant
morbidity and mortality specifically in cases with limited
access to care that might include for example, education
for appropriate feeding. Malnourishment of infants born
with clefts because of feeding problems may enhance the
impact of other mortality risk factors such as infections. A
few studies have reported several-fold increased neonatal
and infant mortality risks among infants born with clefts,
specifically among syndromic forms [11-13]. Further,
there is evidence of a long-term burden even of isolated
forms, mainly in challenges for psychological and social
adjustment [14-16] as well as reduced life expectancy
[17].
Since clefts are readily apparent at birth, they can serve as
sentinels for other birth defects and their impact. We are
studying cleft lip and palate as a model birth defect to
determine whether an increased pediatric care model can
decrease mortality and morbidity in an infant population
born in-hospital mainly to indigent populations in South
America. The primary research aims include evaluating if
neonatal mortality among children born with cleft lip
and/or cleft palate can be decreased by a systematic pedi-
atric intervention over the first month of life, and if sys-
tematic pediatric care over the first two years of life can
improve the neurodevelopment and growth of children
born with isolated forms of cleft lip with cleft palate com-
pared to usual pediatric care. The neurodevelopment and
growth of this latter group will also be compared to those
of healthy control babies without birth defects receiving
usual pediatric care. Secondary research aims include eval-
uating the effectiveness of the pediatric intervention and
follow-up program on other neonatal and two-year of life
health outcomes, which are described below in further
detail.
The study benefits from a well-established consortium of
pediatricians working under the auspices of the Estudio
Colaborativo Latino Americano de Malformaciones Con-
genitas (ECLAMC), a birth defects surveillance program
that has been active in South America since 1967 [18].
Currently, about 80 hospitals are enrolled in ECLAMC
and carry out surveillance of birth defects on approxi-
mately 200,000 births per year. We used this infrastruc-
ture to identify pediatricians who could provide direct
care to infants born with cleft lip and palate and follow
them closely for the first month to ensure that appropriate
medical and surgical interventions were undertaken. The
impact of systematic pediatric care throughout the first
two years of life on health is also being studied in the sub-BMC Pediatrics 2006, 6:9 http://www.biomedcentral.com/1471-2431/6/9
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group with isolated cleft lip and cleft palate using the
same infrastructure.
The objectives of this paper include reporting how the
project was established and describing study design and
interventions. There has been increased emphasis recently
for establishing large-scale clinical trials to study perinatal
and neonatal health interventions in less developed coun-
tries. Recent study reviews have identified the need for
more clinical trials to address several research gaps in the
provision of neonatal care in these settings [19,20]. Fur-
ther evaluation of the effectiveness of alternative models
for neonatal care content and delivery is one emphasized
theme. Yet little empirical guidance on how to optimally
design and implement these trials in less developed coun-
tries is available. As more resources are being allocated
into this field, it is important to share methods of ongoing
large-scale interventional trials. This may help researchers
plan their studies to appropriately adjust interventions,
improve procedures, and estimate adequate budgets. We
hope that sharing our study methods would be of direct
relevance to researchers and funding agencies targeting
this area.
Methods/Design
Setting and participants
Study participants are being recruited in 47 ECLAMC hos-
pitals from 35 cities in Argentina, Brazil, Bolivia, Chile,
Colombia, Ecuador and Venezuela (see list in acknowl-
edgements section). Study participants include live born
infants with cleft lip and/or palate and healthy infants and
their parents. Infants with a typical oral cleft as the only
detected congenital anomaly are considered isolated
cases. Infants with atypical oral clefts (oblique facial clefts,
congenital healed clefts, midline cleft lip, submucous cleft
palate, bifid uvula) are excluded. In this study, syndromic
forms of cleft lip and palate include cases with recognized
syndromes, cases with chromosome abnormalities, cases
with one or more major structural anomalies other than
cleft lip and palate, cases with cognitive delay (IQ or
equivalent less than 80), or cases exposed to recognized
teratogens in utero (phenytoin or valproic acid). Cases
born to mothers who smoked or used alcohol during
pregnancy who otherwise do not meet the syndromic
form criteria listed above are considered isolated cases.
Syndromes are classified using chromosomal analysis
and/or by physical findings, and all cases are reviewed by
at least two experienced dysmorphologists [Eduardo Cas-
tilla, Monica Rittler, Viviana Cosentino, Iêda Orioli, Jeff
Murray].
Inclusion/exclusion criteria
The neonatal prospective group that receives the pediatric
intervention includes infants born with typical clefts of
any etiology or affected segment (lip, gum, hard palate,
soft palate) in participating hospitals between January,
2003 and December, 2005, and diagnosed as eligible
within the first 48 hours after birth, with an initially pro-
jected total of about 696 cases to be available for recruit-
ment. No other inclusion or exclusion criteria are
imposed on this group. Since it was considered unethical
to randomize neonatal subjects into treatment and no
treatment control groups, as there was a strong sentiment
that the intervention forms the current standard of care in
the United States, a retrospective control group born in
2001 and 2002 with clefts in the same hospitals was cho-
sen. This control group is projected to include about 464
cases, yet data are still being processed. This group of
infants had previously received routine pediatric and
medical care offered by their communities during the neo-
natal period. A schema of the study design is shown in Fig-
ure 1.
The two-year study group includes children from the neo-
natal prospective subgroup who are born with isolated
forms of both cleft lip and cleft palate. Children with syn-
dromic forms are excluded, as are twins and children with
birth weight less than 2500 grams or who have complica-
tions other than cleft lip and palate that require systematic
care. A group of healthy controls born without birth
defects and subject to the same exclusion criteria and
whose gestational age is between 37 and 42 weeks are also
included in the two-year study.
Neonatal intervention
The neonatal intervention in the prospective group
involves weekly monitoring and evaluation of infant
health through follow up visits to participating ECLAMC
pediatricians. The visits usually occur at the hospital of
birth or private offices of participating pediatricians; visits
to subjects' homes are encouraged when the weekly visits
are missed. During each of the four neonatal visits extend-
ing to one month of age, the pediatrician conducts a clin-
ical assessment of infant health and growth. Special
emphasis is placed on weight gain, feeding problems, and
medical complications such as hyperbilirubinemia or
infection. The pediatrician also interviews parents for
family and household factors that may affect the infant
health. Based on assessment results, the pediatrician refers
the infant to appropriate health professionals for special-
ized care. Recommendations and instructions to parents
regarding infant needs and optimal care are also provided.
If the child demonstrates a failure to gain weight, physi-
cians will, using standard medical judgment, determine
whether hospital admission is appropriate or whether the
child can be sent home. If sent home, the infant may be
followed at more frequent intervals depending on the
severity of the weight loss or other medical complications.
Any decrease in weight by greater than 10 percent will
require hospital admission and weight decreases betweenBMC Pediatrics 2006, 6:9 http://www.biomedcentral.com/1471-2431/6/9
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0 and 10 percent will have suitability for admission deter-
mined by the referring physician.
The impact of the pediatric intervention on neonatal mor-
tality will be assessed by comparing mortality rates
Study Design Figure 1
Study Design. Figure 1 presents a flowchart of the study design of the neonatal and the two-year subprojects. All infants born 
with a typical form of cleft lip and palate in the study hospitals are enrolled in the neonatal subproject. Only isolated cases with 
both cleft of lip and cleft palate who are singleton births, normal birth weight, and without complications other than cleft lip 
and palate that require systematic care are enrolled at birth in the two-year subproject and randomized into intervened and 
non-intervened groups. A group of healthy controls is matched to the non-intervened group by gender, date and hospital of 
birth at a ratio of 2 to 1. A = Evaluating the impact of the intervention on neonatal mortality. B1 = Evaluating the impacts of 
cleft lip and palate on child's development and family socioeconomic outcomes (Two-year subproject). B2 = Evaluating the 
impact of the two-year intervention on child development and family socioeconomic outcomes.
Neonatal Subproject ------------------------------------------------------------------------------
Two-Year Subproject------------------------------------------------------------------------------
Prospective Interventional Group
(cases born with oral clefts 
between 2003 and 2005) 
Prospective Healthy Control 
Group (births between 2003 and 
2005 and matched at 2 to 1 to 
non-intervened cases with clefts
enrolled in the two-year subproject
 Evaluation at 1 and 2 
years of age
Evaluation at 1 and 2 
years of age
Usual health care  Usual health care 
Evaluation at 1 and 2 
years of age
Remaining cases with oral 
clefts
Isolated cases with both cleft lip with cleft
palate satisfying other inclusion criteria
selected at birth for the two-year
subproject
Non-intervened cases Intervened cases
Randomization (At Birth)
Two-year intervention
Usual health care 
B2 B1
Neonatal intervention
Evaluation at 4 weeks of age Evaluation at 4 weeks of age  A
Retrospective Control 
Group (cases born with
oral clefts between 2001 
and 2002) BMC Pediatrics 2006, 6:9 http://www.biomedcentral.com/1471-2431/6/9
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between the retrospective and prospective study groups.
Birth time periods for the two groups are close and consec-
utive, limiting time changes in conditions such as quality
of health care that may affect mortality and confound the
evaluation of the intervention's impact.
ECLAMC started in 2001 a program titled "ORIENT" to
provide guidance prior to hospital discharge to parents of
infants born with birth defects about appropriate care and
available treatments for the infant [18]. The retrospective
group has also received this standard of care available at
ECLAMC hospitals in addition to the standard of care
available in the community.
Two-year intervention
A second intervention is being carried out on a subset of
children with isolated cleft lip with cleft palate, with an
initially projected total of about 264 cases to be available
for this subproject. Screening for eligibility and enroll-
ment into the two-year subproject occurs at birth. Eligible
children with clefts are randomized at birth into inter-
vened or non-intervened groups. The pediatricians con-
duct a thorough clinical assessment of the development of
intervened children every three months up to two years of
age, including evaluation of physical growth (height,
weight, and head circumference), neurodevelopment,
using the Bayley Infant Neurodevelopmental Screener
(BINS), and language, using the Receptive-Expressive
Emergent Language Test (REEL). The BINS is used to mon-
itor the course of an infant's development and identifies
infants with developmental delays or neurological
impairments who are in need of further diagnostic evalu-
ation [21,22]. The REEL screens for delays in emergent
speech and language development in medically and envi-
ronmentally at-risk children [23,24]. The pediatricians
also perform a dental assessment for the child and record
erupted teeth and any abnormalities, check the nutri-
tional status including feeding content, process, and prob-
lems, and inquire about all child morbidities and
treatments since the last evaluation and overall changes in
health and socioeconomics of family members (e.g.
parental illnesses, changes in employment and marital
status of the parents, and changes in schooling and health
status of siblings). The pediatricians refer the intervened
children to specialized health facilities and professionals
based on their clinical assessments and the practice stand-
ards available for dealing with clefts and emphasize to
parents the importance of compliance with these referrals.
The pediatricians also provide counseling to parents in
order to maintain a healthy and loving familial environ-
ment that provides continuous care to the child.
The healthy control children enrolled in the two-year
study as a normal control group are matched to the non-
intervened cleft group two to one at birth for sex, hospital,
and week of birth. The non-intervened control group of
children with clefts and the healthy control group receive
the standard of care available in their respective commu-
nity according to parental wishes. Both control groups are
assessed at one and two-year follow-ups to measure study
outcomes. The normal control group will be compared to
the non-intervened cases with clefts to assess the impact of
clefting on child health and family socioeconomic out-
comes. The intervened and non-intervened cases with
clefts will be compared to evaluate the effectiveness of the
intervention in lowering the burden of clefting on the
child and the family (see Figure 1).
Randomization procedures in the two-year study
The randomization of cases in the two-year study into
intervened and non-intervened groups is based on a ran-
domization sequence generated by the Data Center at the
Research Triangle Institute (RTI) International, and is
stratified by participating hospitals. The Data Center pro-
vides each pediatrician a set of sealed envelopes that con-
tain a sheet indicating treatment assignment. The
pediatrician administers the randomization procedure by
assigning the next available envelope as each case is
enrolled into the study. Study personnel and subjects are
not blinded to the randomization assignments, but safe-
guards are in place to ensure that assignments are not
known a priori. The pediatrician reports within 24 hours
of each randomization to the Data Center the subject ID,
the tracking number of the randomization envelope used,
and the group assignment for verification, and any incon-
sistencies are readily corrected. The randomization
sequence lists are kept in secure locations at the Data
Center and ECLAMC headquarters.
Study outcomes
The neonatal outcomes include overall mortality at 28
days of life (primary outcome), mortality in subgroups of
isolated and non-isolated cleft groups, hospitalization
days, and refinement of syndromic classification in the
retrospective group. The impact of the neonatal interven-
tion on infant mortality will also be evaluated and phone
interviews are conducted with parents of prospective and
retrospective groups when needed to inquire about child's
survival at one year of age. The primary outcomes of the
two-year study include overall neurodevelopment (meas-
ured by BINS) and weight changes. Secondary outcomes
include performance on four ability areas including neu-
rological functions/intactness, receptive functions, expres-
sive functions, and cognitive processes (measured by the
BINS), speech (measured by REEL), height changes, hear-
ing, timing of cleft surgery, mortality, refinement in syn-
dromic status classification, and emotional, social, and
economic performance of the family.BMC Pediatrics 2006, 6:9 http://www.biomedcentral.com/1471-2431/6/9
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Power analysis
The power analyses prepared prior to study initiation are
reported in Tables 1 and 2 for the neonatal and the two-
year subprojects respectively. The power estimation for
the primary hypothesis of reduction in neonatal mortality
in the prospective group compared to the retrospective
control group assumes a simple random sample scheme
and a probability of Type I error of 0.05. Power is esti-
mated for alternative neonatal mortality rates in both the
prospective and retrospective control groups due to the
lack of robust estimates at the time of study initiation of
baseline mortality rates in the retrospective group and of
potential achievable reductions in neonatal mortality due
to the intervention. Mortality rates of 20, 25, and 30% are
assumed for the retrospective group. The neonatal mortal-
ity rate in the prospective group is also assumed to not
exceed 25% and to be not higher than that of the retro-
spective group (one-sided test). The power calculation for
the neonatal subproject is based on a sample size of 464
cases in the retrospective group and 696 cases in the pro-
spective group. This analysis shows that acceptable power
(>0.7) is available for reductions of about 30% or more in
assumed baseline neonatal mortality rates (See Table 1).
The power analysis to detect differences in means of the
continuous outcomes of the two-year study (e.g. BINS and
REEL scores or weight gain) between the study groups is
also based on alternative effect sizes due to limited infor-
mation available a priori on these parameters and on
alternative sample sizes. In this analysis, power estimation
assumes a paired sample where one subject is selected at
random and another is a matched control (correlation of
0.5 between the subjects in a matched pair). Power is eval-
uated for standardized effect sizes (i.e. mean difference
divided by standard deviation) of 0.15, 0.25, 0.4, and 0.5,
using a Type I error probability of 0.05 and a one sided
test. The analysis shows that acceptable power (>0.7) is
available to detect a standardized effect size of 0.25 or
higher with a sample size of 90 cases per study group. As
an example, a 0.25 standardized effect size for the recep-
tive language quotient of the REEL measure is equivalent
to a 4-point difference from a mean score of 108 with a
standard deviation of 16, which are reference estimates for
samples of normal babies under 36 months of age.
Statistical analysis
The effects of the pediatric interventions on the studied
outcomes will be analyzed using simple statistical tests for
comparisons between intervened and control groups as
well as multivariate regression techniques that account for
potential confounders between the evaluated groups such
as cleft type, baseline health characteristics, family socioe-
conomic status, and for sample clustering across hospitals
and countries of birth. Logistic regression and Cox-pro-
portional hazard models will be used to evaluate differ-
ences in overall neonatal mortality between the
prospective and retrospective groups as well as in sub-
groups of isolated and non-isolated clefts. Similarly,
weight changes and other developmental (e.g. BINS,
REEL, height, etc.) and socioeconomic outcomes (e.g.
maternal employment) will also be compared between
the intervened and non-intervened cleft groups on one
side and between the non-intervened cleft group and the
healthy control group on another side using regression
analyses. Correlation among subjects recruited within the
same hospital (within hospital clustering) and within-
subject correlation in analyses involving multiple obser-
vations per subject will be accounted for by using hierar-
chical/mixed models or Generalized Estimating
Equations (GEE) methods or by applying robust estima-
tors for the variance-covariance of regression parameters.
Country indicators will be included as covariates in mul-
tiple country analyses. Further analyses will also evaluate
differences in primary characteristics (e.g. cleft type, birth
weight) between subjects retained in the study and those
who drop out and further adjustment for participation
propensity will be applied if real differences emerge.
Table 1: Power to Detect Differences in Neonatal Mortality Proportions
Neonatal Mortality in Retrospective Group Neonatal Mortality in Prospective Group Power
0.20 0.12 0.97
0.15 0.68
0.17 0.34
0.25 0.15 0.99
0.17 0.94
0.20 0.61
0.22 0.30
0.30 0.15 >0.99
0.17 >0.99
0.2 >0.99
0.22 0.98BMC Pediatrics 2006, 6:9 http://www.biomedcentral.com/1471-2431/6/9
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Data collection and management
ECLAMC maintains birth records on all participants
[18,25]. Updated data on the retrospective group is col-
lected through abstraction of medical records and through
phone or home interviews of parents. The pediatricians
collect data for the prospective group at birth and at the
periodic follow up evaluations in the neonatal and two-
year subprojects. Specific data collection forms and out-
come measures were developed for the purposes of this
study. Samples of data forms are available from the
authors on request. Data are entered into personal digital
assistants (PDAs) in a system designed and implemented
by the Global Network for Women's and Children's
Health Research Data Coordinating Center at RTI. Data
are transferred on a routine basis from participating hos-
pitals to the study database server in Buenos Aires, and
then to RTI via the Internet in a secure, encrypted file with
personal identifiers stripped. RTI routinely reports to the
National Institute of Child Health and Development
(NICHD) appointed Data Monitoring Committee that
oversees study progress and outcomes.
Personnel training
In order to prepare the pediatricians from ECLAMC for
participation in the study, training sessions were carried
out mostly in conjunction with the annual ECLAMC
meetings. In addition to study design and procedures,
focused training was provided for the use of PDAs for data
collection and for administration of the developmental
instruments (BINS and REEL). Both the BINS and the
REEL were instruments not commonly used in South
America. Following approval from the commercial pro-
viders, both were translated and back translated into
Spanish and Portuguese. A three-day instructional semi-
nar on the use of the BINS and REEL included power point
presentations, training videotapes, practice sessions and
written instructions. These instruments were enthusiasti-
cally received by participating pediatricians and there
have been few concerns expressed over their implementa-
tion. We are currently using English language norms for
comparison but are working on developing both Spanish
and Portuguese versions of the BINS. Training in the use
of the PDAs as well as in methods of electronic data trans-
fer provided individualized tutoring in software/hardware
use based on the needs and experience of each individual.
Retraining is carried out on an annual basis with a pri-
mary focus on new and updated procedures.
Informed consents
Signed informed consent protocols were established after
several iterations with local, Iowa, and RTI Institutional
Review Boards (IRBs) that included translations and back
translations from Spanish and Portuguese to English. Sep-
Table 3: Study Pediatricians
Responsible professional City Country
Rittler, Mónica Buenos Aires Argentina
Rottenberg, Daniela Buenos Aires Argentina
Cosentino, Viviana Buenos Aires Argentina
Jewtuszyk, Mónica Buenos Aires Argentina
Lerner, Mario Gualeguaychú Argentina
Mussi, Margarita Rosario Argentina
Ermini, Mónica La Plata Argentina
Cárpena, Luisa Córdoba Argentina
Chirino, Andrea Córdoba Argentina
Echegaray, Adriana Córdoba Argentina
Negri, Carlos San Martín Argentina
Menzio, Mónica San Luis Argentina
Saleme, César Tucumán Argentina
Deguer, Carlos Bahía Blanca Argentina
Lombardelli, Rodolfo Esquel Argentina
Mereb, Juan Carlos El Bolsón Argentina
Rueda, Saúl La Paz Bolivia
Nogueira, Áurea Florianópolis Brazil
Canonaco, Rosane Sao Paulo Brazil
Leite, Julio César Porto Alegre Brazil
Cavalcanti, Denise Campinas Brazil
Ternes-Pereira, Eliana Florianópolis Brazil
Abath, Cristina Joao Pessoa Brazil
Acosta, Angelina Salvador Brazil
Nazer-Herrera, Julio Santiago Chile
Ojeda, María Elena Rancagua Chile
Canessa, Aurora Linares Chile
Wettig, Elisabeth Puerto Montt Chile
Mellado, Cecilia Santiago Chile
Farfán, Victor Talca Chile
Díaz, Marcela Santiago Chile
Zarante, Ignacio Bogotá Colombia
García, Natalia Bogotá Colombia
Villegas, Carlos A. Manizales Colombia
Luna Ballén, Ana M. La Mesa Colombia
Cristancho, Camilo Ubaté Colombia
Montalvo, Germán Quito Ecuador
Toscano, Mario Manabi Ecuador
Girón, Cecibel Manabi Ecuador
Camacho, Antonio Ibarra Ecuador
Sacoto, Adriana Cañar Ecuador
Martínez, Ernesto Azogues Ecuador
Cedeño, Rosa Maracaibo Venezuela
Jatar Senior, Braulio Coro Venezuela
Table 2: Power to Detect Differences in Means of Continuous 
Outcomes in the Two-Year Study
Sample Size per Group Standardized Effect Size
0.15 0.25 0.4 0.5
60 0.30 0.60 0.92 0.98
90 0.40 0.76 0.98 >0.99
120 0.49 0.85 >0.99 >0.99
150 0.55 0.91 >0.99 >0.99
160 0.59 0.93 >0.99 >0.99
170 0.61 0.94 >0.99 >0.99BMC Pediatrics 2006, 6:9 http://www.biomedcentral.com/1471-2431/6/9
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arate signed informed consents are being utilized for the
neonatal and two-year subprojects among the prospective
group. In case of illiteracy, ECLAMC pediatricians read the
informed consent and fully explain its content to the
mother or legal guardian of the eligible infant. Confirma-
tion is obtained via thumbprints in this case in the pres-
ence of a witness. For the retrospective data collection,
verbal consent is obtained from the parent or legal guard-
ian for participation.
Discussion
This paper describes the methods of a study that is evalu-
ating the effectiveness of a model of care that pediatri-
cians, even in difficult settings, may provide to improve
survival and health of children born with birth defects. We
believe it is important to document the feasibility of con-
ducting international collaborative clinical trials aimed at
prevention and treatment of craniofacial anomalies and
other anomalies as strategies to decrease the global bur-
den imposed by birth defects. The intervention in this
project is consistent with recommendations of the Insti-
tute of Medicine (IOM) to reduce the impact of birth
defects in the developing world by providing better treat-
ments for affected children [26]. The IOM report high-
lights the importance of early thorough assessments to
better identify existing anomalies and define the treat-
ment plans for children with birth defects.
Isolated forms of oral clefts pose larger risks for morbidity
and challenged development than for mortality among
affected infants and children. It is therefore expected that
the pediatric intervention may be more effective in
improving these outcomes than in reducing the mortality
risk in this group.
This study is readily expandable to include infants born
with other potentially lethal anomalies that can benefit
from early recognition and referral. Neural tube defects
and congenital heart disease would be among the com-
mon non-cleft birth defects where early intervention may
prove life saving until appropriate surgical or medical care
can be completed. Furthermore, this intervention may be
studied among infants born preterm and/or at low birth
weight. Up to 28% of worldwide neonatal deaths are
attributed to prematurity, and up to 80% of neonatal
deaths occur among children born at low birth weight
[3,4], a highly prevalent condition specifically in develop-
ing countries where 16% of live births are underweight
[27], forming about 95% of worldwide underweight
births. Other prevention based approaches such as the
folic acid food fortification program in Chile that has
decreased neural tube defects by at least 30% in the last
three years [28] should be used in conjunction with pro-
grams like the one described here that addresses the needs
of infants born with birth defects.
The study is being successfully implemented using the
preexisting infrastructure of the ECLAMC birth defects
surveillance program. The study implementation strate-
gies have a relatively low cost as they rely on an existing
infrastructure and a group of dedicated physicians and
their colleagues. This approach will easily be transporta-
ble to other sites and hypotheses. In future studies we
hope to include parents of affected children as members
of peer support groups. They can serve as physician
extenders to enhance attendance at interventional and fol-
low-up visits and to sustain the intervention in the com-
munity if it proves to be effective. Since the studied
interventions are of tolerable cost and use existing person-
nel, the long-term prospects are good for continuing and
expanding these research efforts.
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